Biomarkers of aortic valve stenosis: Should we rely on a single one?

[1]  T. Çimen,et al.  Calcific aortic stenosis and its correlation with a novel inflammatory marker, the lymphocyte/monocyte ratio. , 2016, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.

[2]  S. Akdağ,et al.  Platelet-to-Lymphocyte Ratio May Predict the Severity of Calcific Aortic Stenosis , 2015, Medical science monitor : international medical journal of experimental and clinical research.

[3]  M. Pencina,et al.  Risk scores and biomarkers for the prediction of 1-year outcome after transcatheter aortic valve replacement. , 2015, American heart journal.

[4]  A. Avcı,et al.  The Relationship between Neutrophil/Lymphocyte Ratio and Calcific Aortic Stenosis , 2014, Echocardiography.

[5]  J. Park,et al.  Association of inflammation, myocardial fibrosis and cardiac remodelling in patients with mild aortic stenosis as assessed by biomarkers and echocardiography , 2014, Clinical and experimental pharmacology & physiology.

[6]  Dong Chen,et al.  Indexes of von Willebrand factor as biomarkers of aortic stenosis severity (from the Biomarkers of Aortic Stenosis Severity [BASS] study). , 2013, The American journal of cardiology.

[7]  P. Kala,et al.  Prognostic Utility of Biomarkers in Predicting of One-Year Outcomes in Patients with Aortic Stenosis Treated with Transcatheter or Surgical Aortic Valve Implantation , 2012, PloS one.

[8]  A. Leite-Moreira,et al.  Understanding the molecular and cellular changes behind aortic valve stenosis. , 2012, Current pharmaceutical biotechnology.

[9]  K. Teo,et al.  Effect of rosuvastatin on C-reactive protein and progression of aortic stenosis. , 2011, American heart journal.

[10]  A. Galloway,et al.  Validation of plasma biomarkers in degenerative calcific aortic stenosis. , 2010, The Journal of surgical research.

[11]  R. Sainger,et al.  Insights into the use of biomarkers in calcific aortic valve disease. , 2010, The Journal of heart valve disease.

[12]  K. Teo,et al.  Effect of Lipid Lowering With Rosuvastatin on Progression of Aortic Stenosis: Results of the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) Trial , 2010, Circulation.

[13]  J. Chambers,et al.  Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. , 2008, The New England journal of medicine.

[14]  R. Prescott,et al.  A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. , 2005, The New England journal of medicine.

[15]  J. Garot,et al.  Predictors of outcome in patients with severe aortic stenosis and normal left ventricular function: role of B-type natriuretic peptide. , 2004, European heart journal.

[16]  C D Naylor,et al.  Analysis of deaths while waiting for cardiac surgery among 29 293 consecutive patients in Ontario, Canada , 1998, Heart.

[17]  Helmut Baumgartner,et al.  Guidelines on the management of valvular heart disease The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology , 2007 .